Prevagen Side Effects: What Is Reported, What Is Studied, and What Is Not
Roon Team
Prevagen Side Effects: What Is Reported, What Is Studied, and What Is Not
The prevagen side effects most frequently listed are headache, dizziness, nausea, constipation, edema, raised blood pressure, and nervousness. Those come from ingredient monographs and adverse-event reports, not from a comparative trial proving cause. The manufacturer's own 90-day study reported no increase in serious adverse events over placebo. A 2012 FDA warning letter described more than 1,000 adverse-event reports the company had received but had not forwarded to FDA. None of that establishes causation. Sorting those three bodies of evidence apart is the point of this page.
Three Kinds of Evidence, and What Each One Can Tell You
Every question about Prevagen safety draws from one of three sources, and each answers a different question.
Trial data comes from controlled studies comparing treatment to placebo. For apoaequorin, the usable trial is one study, 218 people, 90 days.
Spontaneous reports are complaints filed after something goes wrong. They record what happened to someone taking the product. They do not prove the product caused it, because there is no comparison group.
Absence of data is its own category. Questions never studied cannot be answered "safe" or "unsafe." They are open.
What Is in the Capsule
The active ingredient in Prevagen is apoaequorin, a lab-made recombinant protein modeled on a calcium-binding protein found in the jellyfish Aequorea victoria. It is not extracted from jellyfish tissue. That distinction matters for allergenicity questions (more on that below).
| Version | Apoaequorin per capsule | Other ingredients | Serving |
|---|---|---|---|
| Prevagen Regular Strength | 10 mg | Varies by formulation | 1 capsule daily |
| Prevagen Extra Strength | 20 mg | Some versions add vitamin D | 1 capsule daily |
Some formulations also carry vitamin D. Read your own label. Formulations vary by SKU and retailer.
Commonly Reported Apoaequorin Side Effects
The Merck Manual's 2025 professional review lists reported apoaequorin side effects as headache, dizziness, nausea, memory problems, difficulty sleeping, and anxiety. In combination products, increased or decreased blood pressure may occur. Other reported effects in ingredient monographs include constipation, edema (fluid-related swelling), and nervousness, though none of these appear in the Merck Manual's apoaequorin entry.
The Merck Manual also states plainly: "Overall, the safety of apoaequorin is not known."
These are reports, not proven effects. The list comes from ingredient monographs and post-market complaints, not from a trial comparing rates against placebo. That does not mean the effects are not real. It means nobody has measured their frequency against a control group in a way that establishes cause.
What the 90-Day Trial Recorded
The manufacturer's primary study, the Madison Memory Study, was a randomized, double-blind, placebo-controlled trial run by Quincy Bioscience. It enrolled 218 community-dwelling adults aged 40 to 91 with self-reported memory concerns: 145 on 10 mg apoaequorin daily, 73 on placebo. All four authors were Quincy Bioscience employees.
The Alzheimer's Drug Discovery Foundation summarized the safety picture, noting that widespread consumer use and a 90-day randomized controlled trial in older adults suggest that apoaequorin is well-tolerated. In the trial itself, only 2 participants out of 218 withdrew due to adverse events, one from each group (irritability in the apoaequorin group, despondence and lethargy in the placebo group).
That is reassuring as far as it goes. But a single 90-day trial in 218 people cannot detect a rare adverse event. A side effect occurring in 1 in 500 users could easily never appear in a study this small. And 90 days tells you nothing about six months or two years.
The 2012 FDA Warning Letter
On October 16, 2012, FDA sent a warning letter to Quincy Bioscience. An inspection found records of more than 1,000 adverse events and product complaints reported to the company between May 2008 and December 1, 2011, including seizures, strokes, worsening symptoms of multiple sclerosis, heart arrhythmias, chest pain, vertigo, tremors, and syncope. Some resulted in hospitalization. As of the start of the inspection, only two had been reported to FDA.
Two things need to be clear.
First, the regulatory violation was the failure to forward reports. Dietary supplement manufacturers are legally required to report serious adverse events to FDA. Quincy had more than 1,000 reports on file and had forwarded two.
Second, a report is not a proven cause. These were events in people taking the product. Without a comparison group, you cannot know whether the same events would have occurred at the same rate in people not taking it. Seizures, strokes, and arrhythmias occur in the general population at baseline rates. Spontaneous reporting systems detect signals, not prove causation.
The Liver Question
For anyone wondering about liver safety specifically, the NIH's LiverTox database gives apoaequorin a likelihood score of E: unlikely cause of clinically apparent liver injury. That is the lowest risk category on the A-to-E scale. The entry notes that in the human studies that have been published there were no reports of serum enzyme elevations occurring during therapy and no mention of serious adverse events or hepatotoxicity.
This is one of the more concrete safety findings available, because liver injury is well-characterized and enzyme elevations are straightforward to measure.
Drug Interactions and Who Should Ask First
The honest answer: there is almost no data. The Merck Manual states that "the risk for serious drug interactions with apoaequorin is not known." WebMD notes the supplement "hasn't been studied extensively in people, so we don't know much about potential side effects or drug interactions."
That is not "no interactions exist." It means no one has looked. Groups who should check with a pharmacist or prescriber before starting apoaequorin:
- Anyone taking multiple prescription medications (polypharmacy risk)
- Anyone with kidney or liver disease
- Anyone who is pregnant or breastfeeding
- Anyone with a history of allergic reactions to seafood or shellfish proteins
On that last point: the apoaequorin in Prevagen is a recombinant protein produced in a lab, not material from jellyfish. Whether that eliminates allergenicity risk for shellfish-sensitive individuals has not been specifically studied. Ask your allergist.
Is Prevagen Safe for Seniors?
The Madison Memory Study enrolled adults aged 40 to 91, so older adults are actually the population closest to what was studied. The ADDF's summary that the ingredient appears well-tolerated is based on that trial and on broad consumer use.
The honest caveats for this age group: polypharmacy is common in people over 65, and no interaction data exists. The safety database is small (218 people, 90 days). The financial cost is its own consideration on a fixed budget, with Extra Strength capsules typically priced in the range of $60 to $65 for a 30-count bottle at major retailers. For a look at what sits on pharmacy shelves for brain health, evidence varies widely. For older adults exploring energy and focus supplements, the same principle applies: check the evidence and check with your doctor.
One rule worth stating plainly: new or worsening memory problems, confusion, or personality changes are a reason to see a clinician, not a reason to adjust a supplement.
A Note on the Legal Record
A jury found certain Prevagen memory-improvement advertising claims misleading in February 2024, and a federal court ordered Quincy Bioscience to cease those claims on December 6, 2024. The company appealed to the Second Circuit, where oral arguments were heard on February 26, 2026; the appeal is pending as of September 2026. The product remains legally on sale. For context on how supplement regulation works in the U.S., that link goes deeper.
What Is Simply Not Known
The following questions have no published human data answering them:
- Long-term safety beyond 90 days. No trial has followed apoaequorin users past three months.
- Drug interactions. No formal interaction studies with common prescription medications have been published.
- Effects in kidney or liver impairment. Not studied.
- Effects in anyone under 40. The trial population started at age 40.
- Dose-response safety. The trial tested 10 mg. Extra Strength uses 20 mg. Higher-dose safety has not been independently studied in humans.
"Not studied" is not the same as "dangerous." It means the question is open.
Separating Reports from Causes
Prevagen side effects fall into three categories: a small trial that found the ingredient well-tolerated over 90 days, a large set of spontaneous reports that document what consumers experienced without proving cause, and a list of questions that have never been studied. The right move for anyone with concerns is to bring their medication list to a pharmacist and ask whether apoaequorin fits. For a wider look at what memory-supplement evidence actually supports, the answers may surprise you.
Frequently Asked Questions
What are the most common Prevagen side effects?
Headache, dizziness, and nausea are the most commonly reported. The Merck Manual also lists memory problems, difficulty sleeping, anxiety, and blood pressure changes (in combination products). Constipation and edema appear in other ingredient monographs but not in this source. These come from ingredient monographs and consumer reports, not from a controlled trial measuring rates against placebo.
Can Prevagen raise your blood pressure?
Hypertension appears in the list of reported adverse events. The Merck Manual notes that in combination products, increased or decreased blood pressure may occur. No controlled trial has established a causal link between apoaequorin and blood pressure changes. If you are monitoring blood pressure or taking antihypertensives, check with your prescriber before starting any new supplement.
Is Prevagen safe for seniors?
Older adults are the closest match to the studied population (ages 40 to 91). The ADDF describes apoaequorin as well-tolerated based on that 90-day trial and consumer use data. The caveats: the trial was small, short, and manufacturer-run, and no drug-interaction data exists, a real concern for older adults on multiple medications.
Did Prevagen cause seizures and strokes?
The 2012 FDA warning letter described reports of seizures, strokes, and other serious events that consumers had filed with the company. These were reports, not proof of causation. The regulatory issue was Quincy Bioscience's failure to forward those reports to FDA, not a finding that the product caused them.
Does Prevagen interact with medications?
No formal drug-interaction studies for apoaequorin have been published. The Merck Manual states the interaction risk is "not known." Anyone on prescription medications should consult a pharmacist or prescriber before adding apoaequorin.
Is Prevagen safe to take long term?
No one knows. The longest controlled trial lasted 90 days. The Alzheimer's Drug Discovery Foundation notes that safety has not been carefully evaluated for doses higher than the standard (10 mg daily), longer periods of treatment, or for vulnerable patients. Long-term safety is an open question, not a settled one.
Further Reading
- CVS Brain Supplements: A Science-Based Guide
- Best Energy Supplements for Seniors
- Nootropics for Memory: Complete Guide
- Vinpocetine: Nootropic Evidence and FDA Scrutiny
When the Goal Is Afternoon Alertness, Not a Daily Supplement Stack
Prevagen's safety profile is limited by a short evidence base: one 90-day trial in 218 people, no published drug-interaction studies, and an open question on long-term use. For someone whose actual concern is brain health over months or years, that conversation belongs with a clinician, not a supplement label.
Roon sits in a different category entirely. It is not a daily cognitive supplement and makes no memory or brain-health claim. It is a zero sugar sublingual caffeine pouch (80 mg caffeine, 60 mg L-theanine, 25 mg methylliberine, 5 mg theacrine) built for acute alertness across a 6 to 8 hour working window. Its 80 mg of caffeine is below the doses studied in caffeine-and-memory research, so memory benefits should not be expected. Stop at least 8 hours before bed. Subscriptions start from $9.16 per tin, or as little as $0.61 per pouch. One-time 4-tin orders are $15.00 per tin.
Different products answer different questions. If yours is about staying sharp through a single work block, Roon was designed for that and nothing more.
Written by Roon Team
